Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Jason Study
2024-517796-21-00Phase 3Authorised
- Sponsor
- Fondazione Arianna Anticoagulazione
- Start
- Aug 2019
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) comparing Sulodexide (VESSEL) with Placebo (2 arms). Primary endpoints: Primary efficacy endpoint and Primary safety endpoint. Planned start Aug 2019; status: authorised.
02
Drugs
sulodexide
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on 2024-517796-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517796-21-00.